28.03.2007 17:58:00
|
Mintz Levin Advises CVS Corporation on its Acquisition of Caremark Rx, Inc.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., a full-service,
480-lawyer AmLaw 100 firm with offices throughout the U.S. and in the
U.K., announced it advised CVS Corporation (NYSE: CVS) in its
acquisition of Caremark Rx, Inc.(NYSE: CMX), the leading pharmacy
benefit services company (PBM).
Mintz Levin represented CVS in the antitrust aspects of the transaction,
including the Hart-Scott-Rodino review of the transaction by the Federal
Trade Commission (FTC). The FTC allowed the initial HSR waiting period
to expire without requesting additional information. Mintz Levin also
represented CVS in the FTC’s antitrust review
of Express Scripts’ (NYSE: ESRX) hostile offer
to acquire Caremark. The FTC issued an additional request for
information regarding the Express offer, giving the CVS transaction a
decisive timing advantage.
In addition, Mintz Levin advised CVS on the health care regulatory and
real estate aspects of the transaction. The Firm continues to work
actively with CVS/Caremark on the integration and implementation of the
combined company’s business plan.
The transaction, valued at approximately $27 billion, combines one of
the nation’s leading pharmaceutical services
companies with the nation’s largest retail
pharmacy chain. The merger is widely considered to be a transformative
event for the health care services market in the United States. The
newly merged company, CVS Caremark, will be headquartered in Woonsocket,
Rhode Island and CVS CEO, Tom Ryan, will be the CEO.
Mintz Levin members Bruce Sokler, Bruce Metge, and Fernando Laguarda
headed the antitrust team on the transaction. Health care members Robert
Clark, Hope Foster and Ellen Janos advised on the health care regulatory
aspects. Members Stephen Friedberg and Andrew Urban handled the real
estate aspects.
"We were delighted to assist our client of
over 20 years, CVS, in the most important acquisition in the Company’s
history and one that promises to be a ‘game
changer’ in the market for health care
services,” said Andrew R. Urban, co-managing
member of Mintz Levin. "We look forward to
assisting CVS/Caremark in implementing the transformative business plans
the merged company intends to pursue for the benefit of consumers and
the marketplace.” Mintz Levin is an AmLaw 100 law firm with offices in the US and the
UK. The firm has exceptional depth in a broad range of practice
areas, but our clients recognize that what sets us apart from other law
firms is our industry focus. By truly understanding business
drivers and industry trends, we are able to provide our clients with
more than just legal advice. We provide legal solutions to our
clients' business issues. Since 1933, our lawyers have
represented entrepreneurs, emerging growth companies, government
agencies, and leaders in primary industries that include Life
Sciences/Biotechnology; Technology & Communications; Financial Services
& Insurance; Healthcare; Real Estate, Hospitality & Construction; and
Retail & Consumer Products. Our practical knowledge combined
with our industry expertise enables us to provide our clients with
enterprise legal advice that gives their business a competitive
advantage in the marketplace. For detailed information on the firm we
invite you to visit www.mintz.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Caremark Rx Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Caremark Rx Inc.mehr Analysen
Indizes in diesem Artikel
S&P 500 | 5 918,25 | 0,16% |